Table 1.

Human studies based on ONJ.

Author/Year	Brand of drug/administration route	Medication period prior to complication	number of cases	number of cases of ONJ
Holzinger et al. / 2014 (22)	Zoledronic acid / IV	83±50months	NA	13
	Pamidronate / PO
	Ibandronate/ PO
	Alendronate/ PO
Koka et al. / 2010 (23)	Alendronate / PO	>60 months	55	0
Memon et al. / 2012 (8)	Alendronate/ PO	9 Years	100	NA
	Ibandronate/ PO
	Risedronate/ PO
Bell et al. / 2008 (6)	Alendronate/ PO	6 months to 11 years	42	0
	Ibandronate/ PO
	Risedronate/ PO
Al-Sabbagh et al. / 2015 (24)	Alendronate/ PO	≥3 years	20	0
	Ibandronate/ PO
	Risedronate/ PO
Yip et al. / 2012 (25)	Bisphosphonates/ PO	6 years	1460	NA
Jacobsen et al. / 2013 (16)	Zoledronic acid/ IV	5 years	110	14
	Pamidronate/ IV
	Alendronate/ PO
	Ibandronate/ PO
López-Cedrún et al. / 2013 (26)	Alendronate/ PO	3 years	9	9
	Ibandronate/ PO
	Risedronate/ PO
Diniz-Freitas et al. / 2012 (27)	Alendronate/ PO	6 to 132 months	20	20
	Ibandronate/ PO